Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The FDAs Pharmacy Compounding Advisory Committee (PCAC) will review seven peptides to potentially allow compounders to produce them
A.CannonM
Findings from fat cells or other early testing do not always produce the same results
Medical Disclaimer This blog post is intended for educational purposes only and does not constitute medical advice
Composition GHK-Cu: 50 mg BPC-157: 10 mg TB-500 (Thymosin Beta 4): 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Combined evaluation of copper peptide, BPC-157, and TB-500 in in-vitro or ex-vivo assay systems Assay development, including chromatographic separation of three co-formulated peptides Stability characterization of a three-analyte lyophilized blend under laboratory storage conditions Method documentation for HPLC/LC-MS identity and purity assessments Documentation Analysis Report Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
Beyond these findings, clinical outcomes data in this population are limited, underscoring the gap between pharmacokinetic concerns and available evidence
US$ 23.46
US$ 24.24
US$ 26.38
US$ 20.56
